These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 31133366)

  • 1. Survival trends in glioblastoma and association with treating facility volume.
    Aulakh S; DeDeo MR; Free J; Rosenfeld SS; Quinones-Hinojosa A; Paulus A; Manna A; Manochakian R; Chanan-Khan AA; Ailawadhi S
    J Clin Neurosci; 2019 Oct; 68():271-274. PubMed ID: 31133366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved survival of glioblastoma patients treated at academic and high-volume facilities: a hospital-based study from the National Cancer Database.
    Zhu P; Du XL; Zhu JJ; Esquenazi Y
    J Neurosurg; 2020 Feb; 132(2):491-502. PubMed ID: 30771780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
    Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
    J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.
    Fabbro-Peray P; Zouaoui S; Darlix A; Fabbro M; Pallud J; Rigau V; Mathieu-Daude H; Bessaoud F; Bauchet F; Riondel A; Sorbets E; Charissoux M; Amelot A; Mandonnet E; Figarella-Branger D; Duffau H; Tretarre B; Taillandier L; Bauchet L
    J Neurooncol; 2019 Mar; 142(1):91-101. PubMed ID: 30523606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.
    Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Ciner F; Mertsoylu H; Tufan K
    J Neurooncol; 2018 Sep; 139(2):411-419. PubMed ID: 29696530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparities in glioblastoma survival by case volume: a nationwide observational study.
    Raj R; Seppä K; Luostarinen T; Malila N; Seppälä M; Pitkäniemi J; Korja M
    J Neurooncol; 2020 Apr; 147(2):361-370. PubMed ID: 32060840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
    Guler OC; Yıldırım BA; Önal C; Topkan E
    Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis.
    Seliger C; Genbrugge E; Gorlia T; Chinot O; Stupp R; Nabors B; Weller M; Hau P;
    Int J Cancer; 2020 Feb; 146(3):803-809. PubMed ID: 30980539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study.
    Ryu JY; Min KL; Chang MJ
    PLoS One; 2019; 14(12):e0225599. PubMed ID: 31790459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between facility volume and mortality of patients with classic Hodgkin lymphoma.
    Goyal G; Tella SH; Funni S; Kommalapati A; Inselman JW; Shah ND; Go RS; Ansell SM
    Cancer; 2020 Feb; 126(4):757-764. PubMed ID: 31714588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
    Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
    Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study.
    Jiang H; Zeng W; Ren X; Cui Y; Li M; Yang K; Elbaroody M; Lin S
    J Neurooncol; 2019 Aug; 144(1):127-135. PubMed ID: 31175579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
    Brenner A; Friger M; Geffen DB; Kaisman-Elbaz T; Lavrenkov K
    Oncology; 2019; 97(5):255-263. PubMed ID: 31288238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma.
    Go RS; Bartley AC; Crowson CS; Shah ND; Habermann EB; Holton SJ; Holmes DR
    J Clin Oncol; 2017 Feb; 35(6):598-604. PubMed ID: 28199819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between hospital volume and receipt of treatment and survival in patients with glioblastoma.
    Koshy M; Sher DJ; Spiotto M; Husain Z; Engelhard H; Slavin K; Nicholas MK; Weichselbaum RR; Rusthoven C
    J Neurooncol; 2017 Dec; 135(3):529-534. PubMed ID: 28836140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
    Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
    J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
    Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
    Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.